PTPRC and melanoma: In addition, flow cytometry analysis verified that the percentage of tumor-infiltrating CD3+ T cells was increased to 16.8% of CD45+ lymphocytes in melanoma after NPSur-C9AP treatment (Fig. 8g, Supplementary Fig. 30a).